GuiZhou SanLi Pharmaceutical Co.,Ltd

Shanghai Stock Exchange 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd Shareholders' Equity for the year ending December 31, 2023: USD 207.09 M

GuiZhou SanLi Pharmaceutical Co.,Ltd Shareholders' Equity is USD 207.09 M for the year ending December 31, 2023, a 15.34% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

GuiZhou SanLi Pharmaceutical Co.,Ltd Shareholders' Equity for the year ending December 31, 2022 was USD 179.55 M, a 10.61% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Shareholders' Equity for the year ending December 31, 2021 was USD 162.33 M, a 7.91% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Shareholders' Equity for the year ending December 31, 2020 was USD 150.43 M, a 60.89% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Shareholders' Equity for the year ending December 31, 2019 was USD 93.50 M, a 24.13% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Shanghai Stock Exchange: 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd

CEO	Mr. Hai Zhang
IPO Date	April 28, 2020
Location	China
Headquarters	Xiayun Industrial Park
Employees	2,282
Sector	Health Care
Industries Pharmaceuticals

Description

GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular and cerebrovascular drugs, digestive medicine, trauma injury medication, rehabilitation medicine, and ophthalmic medicine. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years